Atlas Trials

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Clinical trial NCT06022003 · RECRUITING

Trial details

NCT number
NCT06022003
Sponsor
French Innovative Leukemia Organisation
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
AML, AdultRefractory AMLRelapsed Adult AMLFLT3-TKD MutationFLT3-ITD
Start date
2024-01-13
Primary completion
2026-10-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.